litlas
ログインアカウント作成

Yeon Hee Park

2005–2025 年に発表

別表記
Yeon-Hee Park
139
論文数
21,920
被引用数
55
h 指数
125
i10 指数

被引用数

Yeon Hee Park の年別被引用数1993 年: 被引用 1 件1999 年: 被引用 2 件2005 年: 被引用 2 件2006 年: 被引用 3 件2007 年: 被引用 9 件2008 年: 被引用 26 件2009 年: 被引用 33 件2010 年: 被引用 21 件2011 年: 被引用 31 件2012 年: 被引用 26 件2013 年: 被引用 47 件2014 年: 被引用 36 件2015 年: 被引用 53 件2016 年: 被引用 49 件2017 年: 被引用 53 件2018 年: 被引用 69 件2019 年: 被引用 250 件2020 年: 被引用 580 件2021 年: 被引用 949 件2022 年: 被引用 1,129 件2023 年: 被引用 1,295 件2024 年: 被引用 2,127 件2025 年: 被引用 1,242 件2026 年: 被引用 41 件1994〜1998 年は被引用が無いため表示していません2000〜2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,389 件、この内訳の 21.6%中国: 引用元論文 1,549 件、この内訳の 14%イタリア: 引用元論文 682 件、この内訳の 6.1%イギリス: 引用元論文 556 件、この内訳の 5%フランス: 引用元論文 461 件、この内訳の 4.2%ドイツ: 引用元論文 460 件、この内訳の 4.1%スペイン: 引用元論文 417 件、この内訳の 3.8%韓国: 引用元論文 399 件、この内訳の 3.6%日本: 引用元論文 395 件、この内訳の 3.6%カナダ: 引用元論文 299 件、この内訳の 2.7%オーストラリア: 引用元論文 275 件、この内訳の 2.5%スイス: 引用元論文 240 件、この内訳の 2.2%
0%21.6%その他 26.6%

機関

分野

  • Medicine63.6%
  • Biochemistry, Genetics and Molecular Biology25.9%
  • Immunology and Microbiology3.6%
  • Materials Science3%
  • Computer Science1.2%
  • Engineering1%
  • その他1.7%

トピック

  • HER2/EGFR in Cancer Research8.4%
  • Cancer Immunotherapy and Biomarkers6.8%
  • Breast Cancer Treatment Studies6%
  • Advanced Breast Cancer Therapies5.6%
  • Cancer Genomics and Diagnostics3.5%
  • Monoclonal and Polyclonal Antibodies Research3.2%
  • その他66.5%

共著者

全論文

検索で開く
  1. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

    著者: Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron - New England Journal of Medicine 2022 被引用: 2,548

  2. Pembrolizumab for Early Triple-Negative Breast Cancer

    著者: Peter Schmid, Javier Cortés, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Theodoros Foukakis, Peter A. Fasching, Fátima Cardoso, Michael Untch, Liyi Jia, Vassiliki Karantza, Jing Zhao, Gursel Aktan, Rebecca Dent, Joyce O’Shaughnessy - New England Journal of Medicine 2020 被引用: 3,116

  3. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    著者: Shanu Modi, Cristina Saura, Toshinari Yamashita, Yeon Hee Park, Sung‐Bae Kim, Kenji Tamura, Fabrice André, Hiroji Iwata, Yoshinori Ito, Junji Tsurutani, Joohyuk Sohn, Neelima Denduluri, Christophe Perrin, Kenjiro Aogi, Eriko Tokunaga, Seock‐Ah Im, Keun Seok Lee, Sara A. Hurvitz, Javier Cortés, Caleb Lee, Shuquan Chen, Lin Zhang, Javad Shahidi, Antoine Yver, Ian E. Krop - New England Journal of Medicine 2019 被引用: 1,973

  4. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    著者: Peter Schmid, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Jay Andersen, Debra Patt, Michael Danso, Marta Ferreira, Marie-Ange Mouret-Reynier, Seock-Ah Im, Jin-Hee Ahn, Maria Gion, Sally Baron-Hay, Jean-François Boileau, Yu Ding, Konstantinos Tryfonidis, Gursel Aktan, Vassiliki Karantza, Joyce O’Shaughnessy - New England Journal of Medicine 2022 被引用: 1,145

  5. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

    著者: Javier Cortés, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min Hwan Kim, Ling-Ming Tseng, Vanessa Petry, Chi-Feng Chung, Hiroji Iwata, Erika Hamilton, Giuseppe Curigliano, Binghe Xu, Chiun-Sheng Huang, Jee Hyun Kim, Joanne W.Y. Chiu, Jose Luiz Pedrini, Caleb Lee, Yali Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz - New England Journal of Medicine 2022 被引用: 1,124

  6. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

    著者: Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortés, Henry Gómez, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo - New England Journal of Medicine 2023 被引用: 704

  7. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

    著者: Fabrice André, Yeon Hee Park, Sung‐Bae Kim, Toshimi Takano, Seock‐Ah Im, Giuliano Borges, João Paulo da Silveira Nogueira Lima, Sercan Aksoy, Joaquín Gavilá Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruíz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, François P. Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Wu Cai, Changan Chu, Anton Egorov, Ian E. Krop - The Lancet 2023 被引用: 345

  8. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer

    著者: Woosung Chung, Hye Hyeon Eum, Hae‐Ock Lee, Kyung Min Lee, Han‐Byoel Lee, Kyu-Tae Kim, Han Suk Ryu, Sangmin Kim, Jeong Eon Lee, Yeon Hee Park, Zhengyan Kan, Wonshik Han, Woong‐Yang Park - Nature Communications 2017 被引用: 1,065

  9. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

    著者: Susan M. Domchek, Sophie Postel‐Vinay, Seock‐Ah Im, Yeon Hee Park, Jean‐Pierre Delord, Antoîne Italiano, Jérôme Alexandre, Benoît You, Sara Bastian, Matthew Krebs, Ding Wang, Saiama N. Waqar, Mark C. Lanasa, Joon Haeng Rhee, Haiyan Gao, Vidalba Rocher-Ros, Emma V. Jones, Sakshi Gulati, Anna Coenen-Stass, Iwanka Kozarewa, Zhongwu Lai, Helen K. Angell, Laura Opincar, Pia Herbolsheimer, Bella Kaufman - The Lancet Oncology 2020 被引用: 459

  10. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    著者: Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei‐Chun Hsu, Stephen Chia - The Lancet Oncology 2021 被引用: 349

  11. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

    著者: Peter Schmid, Javier Cortes, Rebecca Dent, Heather L. McArthur, Lajos Pusztai, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Seock‐Ah Im, Michael Untch, Peter A. Fasching, Marie‐Ange Mouret‐Reynier, Theodoros Foukakis, Marta Ferreira, Fátima Cardoso, Xuan Zhou, Vassiliki Karantza, Konstantinos Tryfonidis, Gursel Aktan, Joyce O’Shaughnessy - New England Journal of Medicine 2024 被引用: 419

  12. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

    著者: Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Gia Nemsadze, Richard D. Baird, Yeon Hee Park, Peter S Hall, Timothy Perren, Robert C. Stein, László Mangel, Jean-­Marc Ferrero, Melissa Phillips, John Conibear, Javier Cortés, Andrew Foxley, Elza C. de Bruin, Robert McEwen, Daniel Stetson, Brian Dougherty, Shah‐Jalal Sarker, Aaron Prendergast, Max McLaughlin-Callan, Matthew Burgess, Cheryl Lawrence, Hayley Cartwright, Kelly Mousa, Nicholas C. Turner - Journal of Clinical Oncology 2019 被引用: 389

  13. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome

    著者: Yeon Hee Park, Samir Lal, Jeong Eon Lee, Yoon‐La Choi, Ji Wen, Sripad Ram, Ying Ding, Soo Hyun Lee, Eric L. Powell, Se Kyung Lee, Jong Han Yu, Keith A. Ching, Jae‐Yong Nam, Seok Won Kim, Seok Jin Nam, Ji‐Yeon Kim, Soo Youn Cho, Seri Park, Jin-Ho Kim, Soohyn Hwang, Yu Jin Kim, Vinícius Bonato, Diane R. Fernandez, Shibing Deng, Shuoguo Wang, Hyun‐Tae Shin, Eun‐Suk Kang, Woong‐Yang Park, Paul A. Rejto, Jadwiga Biénkowska, Zhengyan Kan - Nature Communications 2020 被引用: 190

  14. BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

    著者: Peter Schmid, Seock‐Ah Im, Anne Armstrong, Yeon Hee Park, Wei‐Pang Chung, Zbigniew Nowecki, Simon Lord, Piotr J. Wysocki, Yen‐Shen Lu, Hannah Dry, Vatsala Karwe, Ross Stewart, Pia Herbolsheimer, Ana T. Nunes, Kyung Hae Jung - Journal of Clinical Oncology 2021 被引用: 110

  15. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

    著者: Guy Jérusalem, Yeon Hee Park, Toshinari Yamashita, Sara A. Hurvitz, Shanu Modi, Fabrice André, Ian E. Krop, Xavier González, Benoît You, Cristina Saura, Sung‐Bae Kim, Cynthia R. Osborne, Rashmi K. Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin - Cancer Discovery 2022 被引用: 103

  16. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment

    著者: Nicholas C. Turner, Cynthia Huang Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, X. Cynthia, Erica L. Mayer, Yeon Hee Park, Stephen B. Fox, Xiaochun Liu, Sasha McClain, François‐Clément Bidard - Future Oncology 2023 被引用: 78

  17. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Véronique Dièras, Hyo S. Han, Bella Kaufman, Hans Wildiers, Michael Friedländer, Jean-Pierre Ayoub, Shannon L. Puhalla, Igor Bondarenko, Mario Campone, Erik Jakobsen, Mathilde Jalving, Cristina Oprean, Markéta Palácová, Yeon Hee Park, Yaroslav Shparyk, Eduardo Yáñez, Nikhil Khandelwal, Madan G. Kundu, Matthew W. Dudley, Christine K. Ratajczak, David Maag, Banu Arun - The Lancet Oncology 2020 被引用: 321

  18. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis

    著者: Ryan Tan, Whee Sze Ong, Kyung-Hun Lee, Abner Herbert Lim, Seri Park, Yeon Hee Park, Ching‐Hung Lin, Yen‐Shen Lu, Makiko Ono, Takayuki Ueno, Yoichi Naito, Tatsuya Onishi, Geok Hoon Lim, Su-Ming Tan, Han‐Byoel Lee, Han Suk Ryu, Wonshik Han, Veronique Kiak Mien Tan, Fuh-Yong Wong, Seock‐Ah Im, Puay Hoon Tan, Jason Yongsheng Chan, Yoon Sim Yap - BMC Medicine 2022 被引用: 130

  19. The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology

    著者: Kelly A. Hirko, Gabrielle B. Rocque, Erica Reasor, Ammanuel Taye, Alex Daly, Ramsey Cutress, Ellen Copson, Dae‐Won Lee, Kyung-Hun Lee, Seock‐Ah Im, Yeon Hee Park - BMC Medicine 2022 被引用: 120

  20. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures

    著者: Zhengyan Kan, Ying Ding, Jin-Ho Kim, Hae Hyun Jung, Woosung Chung, Samir Lal, Soonweng Cho, Julio Fernandez-Banet, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Yoon‐La Choi, Shibing Deng, Ji‐Yeon Kim, Jin Seok Ahn, Ying Sha, Xinmeng Jasmine Mu, Jae‐Yong Nam, Young‐Hyuck Im, Soo Hyun Lee, Woong‐Yang Park, Seok Jin Nam, Yeon Hee Park - Nature Communications 2018 被引用: 210

  21. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

    著者: Yeon Hee Park, Seock‐Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon‐La Choi, Won‐Chul Lee, Ahrum Min, Vinícius Bonato, Seri Park, Sripad Ram, Dae‐Won Lee, Ji‐Yeon Kim, Su Kyeong Lee, Won‐Woo Lee, Ji‐Sook Lee, Miso Kim, Hyun Seon Kim, Scott L. Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen G. Dann, Yujin Kim, Diane R. Fernandez, Jiwon Koh, Shuoguo Wang, Song Yi Park, Shibing Deng, Eric L. Powell, Rupesh Kanchi Ravi, Jadwiga Biénkowska, Paul A. Rejto, Woong‐Yang Park, Zhengyan Kan - Genome Medicine 2023 被引用: 55

  22. Prevalence and detection of low-allele-fraction variants in clinical cancer samples

    著者: Hyun‐Tae Shin, Yoon‐La Choi, Jae Won Yun, Nayoung K. D. Kim, Sook‐Young Kim, Hyo Jeong Jeon, Jae‐Yong Nam, Chung Lee, Daeun Ryu, Sang Cheol Kim, Kyunghee Park, Eunjin Lee, Joon Seol Bae, Dae Soon Son, Je‐Gun Joung, Jeeyun Lee, Seung Tae Kim, Myung‐Ju Ahn, Se‐Hoon Lee, Jin Seok Ahn, Woo Yong Lee, Bo Young Oh, Yeon Hee Park, Jeong Eon Lee, Kwang Hyuk Lee, Hee Cheol Kim, Kyoung‐Mee Kim, Young‐Hyuck Im, Keunchil Park, Peter J. Park, Woong‐Yang Park - Nature Communications 2017 被引用: 198

  23. Insights Into Breast Cancer in the East vs the West

    著者: Yoon Sim Yap, Yen‐Shen Lu, Kenji Tamura, Jeong Eon Lee, Eun Young Ko, Yeon Hee Park, A‐Yong Cao, Ching‐Hung Lin, Masakazu Toi, Jiong Wu, Soo Chin Lee - JAMA Oncology 2019 被引用: 186

  24. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer

    著者: Masato Takahashi, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Seock‐Ah Im, Jin‐Hee Ahn, Hirofumi Mukai, Chiun‐Sheng Huang, Shin‐Cheh Chen, Min Hwan Kim, Liyi Jia, Xin Tong Li, Konstantinos Tryfonidis, Vassiliki Karantza, Hiroji Iwata, Peter Schmid - JAMA Network Open 2023 被引用: 48